However, since VEGF inhibitors have risks of bleeding, further studies are needed to evaluate the efficacy and safety of chemotherapy containing pemetrexed and bevacizumab in patients with ocular metastasis from NSCLC. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.